Circulating sTREM-1 as a predictive biomarker of pediatric multisystemic inflammatory syndrome (MIS-C). (January 2023)

• Record Type: Journal Article
• Authors: Gonçalves, Guilherme S.; Correa-Silva, Simone; Zheng, Yingying; Avelar, Isabela; Montenegro, Marília M.; Ferreira, Arthur E.F.; Bain, Vera; Fink, Thais T.; Suguita, Priscila; Astley, Camilla; Lindoso, Livia; Martins, Fernanda; Matsuo, Olivia M.; Ferreira, Juliana C.O.A.; Firigato, Isabela; de Toledo Gonçalves, Fernanda; Fernanda B. Pereira, Maria; Artur A. da Silva, Clovis; Carneiro-Sampaio, Magda; Marques, Heloisa H.S.; Palmeira, Patricia
• Is Part Of: Cytokine. Volume 161(2023)
• Publication Date: 2023-01
• Subjects: COVID-19 -- MIS-C -- Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) -- Inflammatory cytokines -- Severity biomarker; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2022.156084
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: Soluble mediators are valuable tools in COVID-19 diagnosis and prognosis. sTREM-1 has been described as a predictor of inflammation severity. sTREM-1 concentrations were markedly higher in MIS-C vs non-MIS-C acute patients. High sTREM-1 concentrations had a significant association with MIS-C development. IL-6, IL-8, and IL-10 concentrations were higher in the acute phase compared with the convalescent phase, regardless of whether the patient developed MIS-C. sTREM-1 in pediatric patients has good predictive accuracy as an early screening biomarker to identify MIS-C cases. Abstract: The exacerbation of the inflammatory response caused by SARS-CoV-2 in adults promotes the production of soluble mediators that could act as diagnostic and prognostic biomarkers for COVID-19. Among the potential biomarkers, the soluble triggering receptor expressed on myeloid cell-1 (sTREM-1) has been described as a predictor of inflammation severity. The aim was to evaluate sTREM-1 and cytokine serum concentrations in pediatric patients during the acute and convalescent phases of COVID-19. This was a prospective study that included 53 children/adolescents with acute COVID-19 (Acute-CoV group); 54 who recovered from COVID-19 (Post-CoV group) and 54 controls (Control group). Preexisting chronic conditions were present in the three groups, which were defined as follows: immunological diseases, neurological disorders, and renal and hepatic failures. The three groups were matched by age, sex, and similar preexisting chronic conditions. No differences in sTREM-1 levels were detected among the groups or when the groups were separately analyzed by preexisting chronic conditions. However, sTREM-1 analysis in the seven multisystemic inflammatory syndrome children (MIS-C) within the Acute-Cov group showed that sTREM-1 concentrations were higher in MIS-C vs non-MIS-C acute patients. Then, the receiver operating curve analysis (ROC) performed with MIS-C acute patients revealed a significant AUC of 0.870, and the sTREM-1 cutoff value of > 5781 pg/mL yielded a sensitivity of 71.4 % and a specificity of 91.3 % for disease severity, and patients with sTREM-1 levels above this cutoff presented an elevated risk for MIS-C development in 22.85-fold (OR = 22.85 [95 % CI 1.64–317.5], p = 0.02 ). The cytokine analyses in the acute phase revealed that IL-6, IL-8, and IL-10 concentrations were elevated regardless of whether the patient developed MIS-C, and those levels decreased in the convalescent phase, even when compared with controls. Spearman correlation analysis generated positive indexes between sTREM-1 and IL-12 and TNF-α concentrations, only within the Acute-CoV group. Our findings revealed that sTREM-1 in pediatric patients has good predictive accuracy as an early screening tool for surveillance of MIS-C cases, even in patients with chronic underlying conditions.